A Post-Marketing Near Real-Time Safety Surveillance of Respiratory Syncytial Virus Vaccine for Guillain-Barre Syndrome (GBS) among Older Adults in the United StatesFirst published 16/08/2024 Last updated 16/08/2024 EU PAS number: EUPAS1000000267StudyPlanned